Libera Bio announced today that it has closed its Seed Round to advance its MPN Technology® into enabling studies and towards the clinic.
- Antibodies delivered via the MPN Technology® are proven in vivo to bind with intracellular cancer targets and shrink tumors, in preclinical studies
- Co-developing two antibodies against different KRAS mutations with a top ten pharma
- Establishing alliances with companies designing novel monoclonal antibodies to deliver them intracellularly using Libera’s MPN Technology®
- Closing its EUR 1.3 million Seed Round